Although MAP (mitogen-activated protein) kinases are implicated in cell proliferation and differentiation in many cell types, the role of MAP kinases in cardiac hypertrophy remains unclear. We examined the role of extracellular signal-regulated protein kinase (ERK), c-Jun N-terminal kinase (JNK) and p38 MAP kinase in angiotensin II (Ang II)-induced hypertrophy compared with phenylephrine-induced hypertrophy in neonatal rat cardiac myocytes. Both Ang II and phenylephrine activated ERKs to a similar extent, whereas phenylephrine caused stronger and more sustained activation of JNK and p38 than Ang II. PD98059, a specific inhibitor of MAPK/ERK kinase (MEK),inhibited Ang II-induced, but not phenylephrine-induced, expression of atrial natriuretic factor (ANF) at both the mRNA and polypeptide levels. SB203580, a specific inhibitor of p38 and some JNK isoforms, did not show significant effects on ANF expression induced by Ang II or phenylephrine. Although PD98059 and dominant-negative MEK1 blocked Ang II-induced activation of the ANF promoter, SB203580 or dominant-negative MEK kinase 1 (MEKK1) showed no effect. Phenylephrine-induced ANF promoter activation was significantly inhibited by SB203580 and dominant-negative MEKK1, but not by PD98059 or dominant-negative MEK1. Dominant-negative Ras inhibited both ERK activation and ANF up-regulation by Ang II, whereas constitutively active forms of Ras and MEK were sufficient to activate the ANF promoter. Dominant-negative Ras also partly inhibited the phenylephrine-induced activation of ANF promoter. PD98059 did not affect other markers of Ang II-induced hypertrophy, such as skeletal α-actin and c-fos expression, increases in the rate of protein synthesis or rapid sarcomeric actin organization. These results suggest that Ang II uses ERK for ANF expression, whereas phenylephrine uses other pathways. The Ras/ERK pathway selectively mediates ANF expression in various phenotypes observed in Ang II-induced hypertrophy. The ERK pathway mediates an agonist-specific and phenotype-specific response in cardiac hypertrophy.
Explants of frog tadpole spinal cord cocultured with blastemas of regenerating hindlimbs provide in vitro evidence that the mesenchymelike cells of the blastema may serve to elicit nerve fiber growth and sprouting into the limb stump. The present study indicates that (1) blastemal mesenchyme results in enhanced, directed nerve fiber growth and its extended survival in defined tissue culture medium; (2) the amount of nerve growth decreases in the presence of blastemas from limbs incapable of complete regeneration; and (3) the quantity of nerve fiber outgrowth decreases as the developmental stage of the spinal cord increases. It is hypothesized that one of the requisites for limb regeneration is the production of a distal population of dedifferentiated cells capable of eliciting nerve fiber outgrowth from competent neural tissue in an amount that is sufficient to promote nerve-dependent regeneration.
Mesenchyme in the hind limbs of Rana pipiens tadpoles may serve as an important influence on the development of specific neural structures involved in limb innervation. Thus a histological quantification of mesenchyme was undertaken to identify landmark stages with respect to mesenchyme presence and neural events. Mesenchyme remained as a high percentage of the limb tissue until stage V (Taylor-Kollros stages, '46), after which it declined dramatically until its virtual absence after stage XI. The volume of mesenchyme, however, was greatest at stages VIII-IX. Periods of high and low mesenchyme content were correlated in time with potential limb involvement in regulating limb innervation and motor neuron loss from the lateral motor columns. This provides additional evidence for developmental relationships between events of the limb and neural tissues.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.